Core Viewpoint - Yatani Group (00789) experienced a significant stock price increase, rising over 48% during trading, with a current increase of 38.33% to HKD 0.142, and a trading volume of HKD 2.2969 million [1] Group 1: Strategic Partnership - Yatani Group announced a strategic cooperation agreement with Baiyunshan Weiyi, aimed at jointly developing products in the health and wellness sector and expanding market reach [1] - The collaboration will focus on innovative products in areas such as natural plant extracts, functional health products, and personal care items [1] - Both companies plan to promote the developed products and existing related products in overseas markets [1] Group 2: Business Development Strategy - The announcement aligns with Yatani Group's recent efforts to expand its sales business in beauty and health products [1] - The board believes that this strategic partnership will leverage Yatani Group's international market and sales platform advantages alongside Baiyunshan Weiyi's technical, brand, and product strengths, creating synergies [1] - This initiative is expected to enrich the company's product portfolio and enhance its core competitiveness in the health and wellness sector, opening new revenue streams [1]

Core Viewpoint - Yatani Group (00789) has seen a significant stock price increase of over 48% during trading, attributed to the announcement of a strategic cooperation agreement with Baiyunshan Weiyi to jointly develop products in the health sector [1] Group 1: Strategic Cooperation - The agreement aims to collaborate on the research and development of products in the health sector, including natural plant extracts, functional health products, and personal care items [1] - Both companies plan to market the developed products and existing related products in overseas markets [1] Group 2: Business Development Strategy - Yatani Group has been actively expanding its sales of beauty and health products in recent years, aligning with the strategic cooperation with Baiyunshan Weiyi [1] - The board believes that this partnership will leverage Yatani's international market and sales platform alongside Baiyunshan Weiyi's technology, brand, and product advantages, creating synergies [1] - This collaboration is expected to enrich Yatani's product portfolio and enhance its core competitiveness in the health sector, potentially opening new revenue streams [1]

Core Viewpoint - The event held in Yantai focused on the theme of "Inheriting Good Traditional Practices and Family Values," showcasing the integration of traditional Chinese medicine culture with modern public welfare initiatives [1][9]. Group 1: Company Initiatives - Baiyunshan Xiaochaihu, a member of the Fortune Global 500 company Guangyao Group, demonstrated its commitment to public welfare through various initiatives, including pandemic donations, rural revitalization, educational support, and cultural inheritance [9]. - The company presented "Good Family Values Commemorative Plaques" to partners during the event, symbolizing the ongoing transmission of these values [9]. Group 2: Cultural and Community Engagement - The event featured family stories from four local families, highlighting the importance of family values and their real-life applications, such as a driver saving a student in distress and stories of ethnic unity and dedication to medical ethics [4]. - Traditional cultural displays and modern artistic performances, including drum music and martial arts, showcased the hope of cultural inheritance and the fusion of traditional and modern elements [6]. Group 3: Audience Interaction - The event included interactive segments such as audience Q&A and games, encouraging participation and enhancing the understanding of traditional Chinese medicine and family values in a relaxed atmosphere [13].

Group 1 - The core point of the news is that Atnini Group has signed a strategic cooperation agreement with Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. to jointly develop products in the health sector and expand market reach, with a cooperation period of one year [1] - The strategic cooperation will focus on joint product development in areas such as natural plant extracts, functional health products, and personal care products [1] - Baiyunshan Weiyi will provide brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion related to health products [1] Group 2 - The cooperation aligns with Atnini Group's business development strategy and long-term layout in the health industry, aiming to leverage the advantages of both companies [2] - The board believes that this strategic cooperation will enhance the product portfolio and core competitiveness in the health sector, potentially opening new revenue sources [2] - The agreement is considered beneficial for the company and its shareholders overall [2]

Group 1 - The core point of the article is that Atnini Group has signed a strategic cooperation agreement with Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. to jointly develop products in the health sector and expand market reach, with a cooperation period of one year [1][2] - The strategic cooperation will focus on joint product development in areas such as natural plant extracts, functional health products, and personal care products [1] - Baiyunshan Weiyi will provide brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion related to health products [1] Group 2 - The cooperation aligns with Atnini Group's business development strategy and long-term layout in the health industry, aiming to leverage the strengths of both companies for synergistic effects [2] - This partnership is expected to enrich Atnini Group's product portfolio and enhance its core competitiveness in the health sector, potentially opening new revenue streams [2] - The board of directors believes that the agreement with Baiyunshan Weiyi is in the overall interest of the company and its shareholders [2]

Group 1 - The core point of the article is the strategic cooperation agreement signed between Yatani Group and Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. to jointly develop products in the health sector and expand market reach [1][2] Group 2 - The strategic cooperation agreement is set for a duration of one year and focuses on joint product development in areas such as natural plant extracts, functional health products, and personal care products [1] - The collaboration aims to leverage Baiyunshan Weiyi's brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion [1] - This partnership aligns with the company's strategy to expand its beauty and health product sales, enhancing its core competitiveness in the health sector and opening new revenue streams [2]

Core Viewpoint - The strategic cooperation agreement between Yatani Group and Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. aims to jointly develop products in the health sector and expand market reach, with a focus on innovation and international marketing support [1][2]. Group 1: Strategic Cooperation Details - The cooperation agreement is set for one year, focusing on joint research and development of products in the health sector, including natural plant extracts, functional health products, and personal care items [1]. - Baiyunshan Weiyi will provide brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion related to health products [1]. Group 2: Business Development Strategy - The partnership aligns with the company's strategy to expand its beauty and health product sales, enhancing its long-term positioning in the health industry [2]. - The board believes that this collaboration will leverage the company's international market advantages and Baiyunshan Weiyi's technical and brand strengths, creating synergies that could enrich the product portfolio and open new revenue streams [2].

本 公 告 乃 由 雅 天 妮 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 向 本 公 司 股 東（「股 東」）及 本 公 司 潛 在 投 資 者 作 出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Artini Holdings Limited 雅天妮集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：789） 自願公告 關於與白雲山維一簽訂戰略合作協議 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 公 告，於 二 零 二 五 年 九 月 十 九 日，本 公 司 與 廣 州 白 雲 山 維 一 實 業 股 份 有 限 公 司（「白雲山維一」）簽 署 了 一 份 戰 略 合 作 協 議 （「合作協議」），旨 在 共 同 研 發 大 健 康 領 域 產 品 及 拓 展 市 場（「戰略合作」）。合 作 期 限 為 一 年。 白 雲 ...

Overview - The core viewpoint of the article highlights the growing demand for traditional Chinese medicine (TCM) transdermal patches due to their advantages such as no first-pass effect, minimal gastrointestinal damage, low toxicity, prolonged efficacy, and ease of use, particularly among populations that cannot take oral medications, like the elderly and children [1][4][8]. Market Size - The market size of TCM transdermal patches in China is projected to reach 14 billion yuan by 2024, accounting for 65.34% of the overall medicinal patch market [1][8]. Market Policies - The Chinese government has implemented various policies to support the development of the TCM industry, including measures to enhance scientific regulation, promote innovation, and improve healthcare quality from 2023 to 2025 [5][6]. Industry Chain - The upstream of the TCM transdermal patch industry includes suppliers of raw materials such as Chinese medicinal herbs, rubber, and various excipients, while the midstream consists of manufacturers of TCM transdermal patches, and the downstream includes medical institutions, retail pharmacies, and online pharmacies [6][7]. Sales Channels - Medical institutions are the primary sales channel for TCM transdermal patches, accounting for over 60% of sales. By the end of 2024, there will be approximately 1.092 million medical institutions in China, with a 2.0% year-on-year growth [7][8]. Competitive Landscape - The top five companies in the TCM transdermal patch market as of Q1 2025 include Qizheng Group, Yunnan Baiyao, Lingrui Pharmaceutical, Hillman Pharmaceutical, and China Resources Pharmaceutical, with Qizheng Group and Yunnan Baiyao leading the market [10][11]. Company Analysis - Qizheng Tibetan Medicine Co., Ltd. is a leading modern Tibetan medicine company with a revenue of 1.175 billion yuan in the first half of 2025, of which 824 million yuan (70.11%) comes from transdermal patch sales [12]. - Lingrui Pharmaceutical Co., Ltd. reported a total revenue of 2.099 billion yuan in the first half of 2025, with a gross profit of 1.707 billion yuan and a gross margin of 81.33% [13]. Development Trends - The demand for TCM transdermal patches is expected to grow due to the aging population and increasing prevalence of musculoskeletal and cardiovascular diseases. Additionally, the shift in health consciousness and the rise of online sales channels will further expand the market [13].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 中國廣州，2025年9月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 白云山 2025 年第二次临时股东大会 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司2025年第二次臨時股東大會會議資料之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 广州白云山医药集团股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 9 月 26 日 第 1 页 共 141 页 白云山 2025 年第二次临时股东大会 目 录 | 一、会议须知……………………………………………………3 | | --- | | 二、会议议程 ...